Lutetium Lu 177 dotatate
- Generic Name
- Lutetium Lu 177 dotatate
- Brand Names
- Lutathera
- Drug Type
- Small Molecule
- Chemical Formula
- C65H87LuN14O19S2
- CAS Number
- 437608-50-9
- Unique Ingredient Identifier
- AE221IM3BB
- Background
A 177Lu-labeled somatostatin analog peptide, Lutetium Lu 177 dotatate belongs to an emerging form of treatments called Peptide Receptor Radionuclide Therapy (PRRT), which involves targeting tumours with molecules carrying radioactive particles that bind to specific receptors expressed by the tumour. Lutetium Lu 177 dotatate may also be referred to as 177Lu-D...
- Indication
Indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults .
- Associated Conditions
- Gastroenteropancreatic Neuroendocrine Tumors
- Associated Therapies
- -
Randomized Phase III of PRRT Versus Interferon
- Conditions
- Interventions
- First Posted Date
- 2013-05-23
- Last Posted Date
- 2016-04-05
- Lead Sponsor
- Jules Bordet Institute
- Registration Number
- NCT01860742
- Locations
- 🇧🇪
UZ Leuven, Leuven, Belgium
🇧🇪Jules Bordet Institute, Brussels, Belgium
177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms
- First Posted Date
- 2010-11-09
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- Ebrahim S Delpassand
- Target Recruit Count
- 143
- Registration Number
- NCT01237457
- Locations
- 🇺🇸
Excel Diagnostics and Nuclear Oncology Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.